



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

November 22, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – November 19, 2021

TOTAL Cases Reported Since 1/22/20

47,587,441

NEW Cases Reported to CDC on 11/19/21

113,816

Change in 7-Day Case Average


+18.0%

Current 7-Day Case Average (11/13/21 - 11/19/21)

92,852

Prior 7-Day Case Average (11/6/21 - 11/12/21)

78,692



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – November 19, 2021

Patients Currently Hospitalized with COVID on 11/19/21

36,975

New Admissions on 11/19/21

5,142

Peak in New Admissions (1/5/21)

17,949

Change in 7-Day Average of New Admissions


+6.4%

Current 7-Day Average of New Admissions (11/13/21 - 11/19/21)

5,627

Prior 7-Day Average of New Admissions (11/6/21 - 11/12/21)

5,288



Daily Change in COVID-19 Deaths, US

January 22, 2020 – November 19, 2021

TOTAL Deaths Reported Since 1/22/2020

770,461

NEW Deaths Reported to CDC on 11/19/21

1,687

Change in 7-Day Death Average

-1.1%

Current 7-Day Death Average (11/13/21 - 11/19/21)


1,048

Prior 7-Day Death Average (11/6/21 - 11/12/21)

1,060


Forecasted Total Deaths by 12/11/21

788,000 to 798,000




Vaccination decreases COVID-19 cases and deaths

COVID-19 Cases,
by vaccination status




COVID-19 Deaths,
by vaccination status



Vaccination decreases COVID-19-associated hospitalizations

COVID-19 Hospitalization,
by vaccination status



“Booster” Shots for SARS-CoV-2 Vaccines



First and foremost



If you have not yet been vaccinated



Get vaccinated!!




Vaccines prevent infections, prevent hospitalizations and save lives



Waning Immunity after COVID-19 Vaccination Among U.S. Veterans, 2021

Waning immunity against infection



■ Vaccine effectiveness (VE) against SARS-CoV-2 infection declined from 87.9% to 48.1% from Feb. to Oct., 2021

■ From July to October 2021 (Delta predominant period), VE against COVID-19 death:

- age <65 years: 73.0% for Janssen, 81.5% for Moderna, 84.3% for Pfizer-BioNTech
- age ≥65 years: 52.2% for Janssen, 75.5% for Moderna, 70.1% for Pfizer-BioNTech

Source: BA Cohn et al. *Science*, 11/4/2021.





The
New England
Journal of Medicine

Established in 1811 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Published online September 15, 2021


Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

YM Bar-On, A Huppert et al.

- Data for period 7/30 – 8/31, 2021 from 1.14 million people aged 60 years and older who had received a 2nd dose of mRNA vaccine at least 5 months earlier
- 12 days or more after the booster dose, the rate of confirmed infection was lower in the booster group than in the non-booster group by a factor of 11.3; the rate of severe illness was lower by a factor of 19.5



Israel: Cumulative Incidence Curves Comparing COVID-19-Related Hospital Admissions, Severe Disease and Death in People Who Received 2 Versus 3 Doses of BNT162b2 Vaccine



Source: N Barda et al. *Lancet*, 10/29/2021.



Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 Booster Vaccine Against COVID-19 Related Symptoms in England: Test Negative Case-Control Study

N Andrews, JL Bernal et al.

- Study in U.K. of people 50+ years who received a booster (3rd) shot of Pfizer-BioNTech vaccine
- Booster increased vaccine effectiveness against symptomatic COVID-19 disease from 44% to 93% for people who had received 2 doses of AstraZeneca vaccine, and from 63% to 94% for people who had received 2 doses of Pfizer-BioNTech vaccine


Study C4591031: Efficacy & Safety of BNT162b2 Booster

- ~10,000 participants ≥ 16 years of age in Brazil, South Africa and United States
- In 2-month interim analysis, efficacy against symptomatic COVID-19 in the boosted group compared to the unboosted group was 95.6%
- Efficacy was consistent irrespective of age, sex, race, ethnicity, comorbid conditions
- Adverse events were consistent with those seen in previous studies

Source: JL Perez (Pfizer), ACIP meeting, 11/19/2021.



Study C4591031: Cumulative Incidence Curve for First COVID-19 Occurrence After Booster Vaccination




Source: JL Perez (Pfizer), ACIP meeting, 11/19/2021.



mRNA-1273 Booster Increases Antibody Titters Against Delta Variant

50 µg Booster after 100 µg Primary Series




■ Substantial increase in post-boost titers against Delta was achieved in both age groups

Source: VRBPAC Presentation, Moderna, 10/14/2021



BNT162b2 Booster Increases Antibody Titters Against Delta Variant



Source: Falsey et al. *NEJM* 9/15/2021



Protection from infection, disease, and death wanes significantly >6 months after the primary series



Data from Israel, the UK and now the US show boosters significantly enhance protection



Protect yourself, your family and your community – get boosted!



Enjoy the holidays!





THE WHITE HOUSE
WASHINGTON

WH.GOV